Key Points
- EVP Neena Patil sold 55,600 shares at an average price of $191.56 for a total of about $10.65 million, reducing her stake by roughly 49.44% to 56,862 shares.
- Multiple insiders — including SVP Mary Elizabeth Henderson, Director Norbert G. Riedel and CAO Patricia Carr — also sold shares in recent filings, which may be viewed as a near‑term negative signal for investor sentiment.
- Jazz reported stronger-than-expected quarterly results (EPS $6.64 vs. $6.49; revenue $1.20B vs. $1.17B) and analysts have raised price targets, leaving a consensus rating of Moderate Buy with an average target of $214.57.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) CAO Patricia Carr sold 1,117 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $190.91, for a total value of $213,246.47. Following the transaction, the chief accounting officer directly owned 9,235 shares in the company, valued at approximately $1,763,053.85. The trade was a 10.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Patricia Carr also recently made the following trade(s):
- On Thursday, February 26th, Patricia Carr sold 1,253 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $194.11, for a total transaction of $243,219.83.
- On Friday, December 5th, Patricia Carr sold 4,660 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $171.20, for a total transaction of $797,792.00.
Jazz Pharmaceuticals Stock Performance
JAZZ opened at $190.46 on Tuesday. The company has a 50 day simple moving average of $170.05 and a two-hundred day simple moving average of $152.44. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.86 and a quick ratio of 1.67. The firm has a market cap of $11.72 billion, a P/E ratio of -31.90, a PEG ratio of 0.38 and a beta of 0.22. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $198.00.
Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, beating analysts' consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The company had revenue of $1.20 billion for the quarter, compared to analysts' expectations of $1.17 billion. During the same quarter in the previous year, the company earned $6.51 EPS. Jazz Pharmaceuticals's revenue for the quarter was up 8.1% on a year-over-year basis. Equities analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.
Jazz Pharmaceuticals News Summary
Here are the key news stories impacting Jazz Pharmaceuticals this week:
- Positive Sentiment: Barclays started research coverage of Jazz, which can increase visibility and liquidity for the stock and sometimes leads to upgrades or renewed investor interest. Jazz Pharmaceuticals (NASDAQ:JAZZ) Research Coverage Started at Barclays
- Neutral Sentiment: A Zacks report examines Jazz's dependence on international sales and the implications for analyst forecasts and the company's growth outlook — useful background but not an immediate catalyst unless the analysis triggers revisions to guidance or estimates. Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know
- Negative Sentiment: Executive vice president Neena M. Patil sold 55,600 shares (≈$10.65M at ~$191.56/share), a nearly 50% reduction in her stake — a large single insider sale that may weigh on sentiment. Neena M. Patil SEC Filing
- Negative Sentiment: Additional senior insider sales: SVP Mary Elizabeth Henderson sold 5,343 shares (~$1.04M) and Director Norbert G. Riedel sold 3,415 shares (~$655.7K); CAO Patricia Carr executed two smaller sales on Feb. 26–27. Collectively these transactions represent meaningful percentage reductions in holdings by multiple insiders and may be interpreted as a near-term negative signal by some investors. Mary E. Henderson SEC Filing Norbert G. Riedel SEC Filing Patricia Carr SEC Filing
Analyst Ratings Changes
JAZZ has been the topic of a number of research analyst reports. Truist Financial boosted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a report on Monday, January 12th. Bank of America lifted their price objective on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a "buy" rating in a research report on Wednesday, February 25th. Royal Bank Of Canada upped their target price on shares of Jazz Pharmaceuticals from $191.00 to $195.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 25th. UBS Group reaffirmed a "neutral" rating and set a $188.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Monday, November 24th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $219.00 price target (up from $147.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 10th. Fourteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $214.57.
View Our Latest Stock Analysis on Jazz Pharmaceuticals
Hedge Funds Weigh In On Jazz Pharmaceuticals
Several institutional investors have recently bought and sold shares of JAZZ. Kennedy Capital Management LLC purchased a new stake in Jazz Pharmaceuticals during the second quarter valued at approximately $1,100,000. Essex Investment Management Co. LLC bought a new position in shares of Jazz Pharmaceuticals during the 3rd quarter valued at approximately $2,697,000. Wedge Capital Management L L P NC bought a new position in shares of Jazz Pharmaceuticals during the 3rd quarter valued at approximately $27,834,000. Sequoia Financial Advisors LLC purchased a new stake in Jazz Pharmaceuticals during the 3rd quarter valued at $605,000. Finally, Aberdeen Group plc bought a new stake in Jazz Pharmaceuticals in the third quarter worth $8,629,000. Institutional investors own 89.14% of the company's stock.
Jazz Pharmaceuticals Company Profile
(
Get Free Report)
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.
Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
